文献速递生殖医学母胎医学

预防线粒体疾病的新型生殖技术

Novel reproductive technologies to prevent mitochondrial disease.
PubMed 文献 · Hum Reprod Update · 2017-01-01

本文综述了核移植(NT)等新型生殖技术用于预防母系遗传线粒体DNA(mtDNA)突变传播的科学证据,检索PubMed至2017年1月并纳入人类受精与胚胎学管理局文件及媒体报告。动物模型显示NT可有效减少异质性mtDNA变异传播,但支持其用于人类mtDNA疾病预防及不孕症治疗的证据仍有限,需稳健的长期评估,产前筛查仍被强烈提倡。

要点

  • NT在动物模型中可有效减少异质性mtDNA变异传播,但人类应用需长期评估。
  • 支持NT用于不孕症治疗的科研证据目前缺乏。
  • 任何ART新疗法须先在动物和人类模型中充分评估方可谨慎临床实施。

核心结论

  • NT技术可减少动物模型中异质性mtDNA变异传播,但需稳健的长期评估。
  • 产前筛查仍被强烈提倡与这些基于IVF的技术联合使用。
  • 支持NT用于不孕症的科研证据目前缺乏。

研究设计与样本

  • 综述检索PubMed数据库至2017年1月,并纳入人类受精与胚胎学管理局相关文件及科学和大众媒体报道。
  • 检索关键词包括「线粒体」「线粒体DNA」「线粒体DNA疾病」「生育力」「植入前遗传学诊断」「核移植」「线粒体替代」「线粒体捐赠」。

主要发现

  • 动物模型显示NT技术可有效减少异质性mtDNA变异传播。
  • 越来越多证据支持NT用于预防人类mtDNA疾病传播。
  • 支持NT及其他新型生殖技术用于不孕症的科研证据目前缺乏。

临床怎么用

  • 任何新的ART治疗须先在动物和人类模型中充分评估,方可谨慎临床实施。
  • 这些创新技术向临床实践转化应仅在高度选择的患者中谨慎采用。
  • 鉴于安全性和有效性数据有限,对任何子代进行密切监测仍至关重要。
  • 产前筛查仍被强烈提倡与这些基于IVF的技术联合使用。

局限性

  • 需要稳健的长期评估。
  • 支持NT用于不孕症的科研证据目前缺乏。
  • 安全性和有效性数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of nuclear transfer (NT) has been proposed as a novel reproductive treatment to overcome the transmission of maternally-inherited mitochondrial DNA (mtDNA) mutations. Pathogenic mutations in mtDNA can cause a wide-spectrum of life-limiting disorders, collectively known as mtDNA disease, for which there are currently few effective treatments and no known cures. The many unique features of mtDNA make genetic counselling challenging for women harbouring pathogenic mtDNA mutations but reproductive options that involve medical intervention are available that will minimize the risk of mtDNA disease in their offspring. This includes PGD, which is currently offered as a clinical treatment but will not be suitable for all. The potential for NT to reduce transmission of mtDNA mutations has been demonstrated in both animal and human models, and has recently been clinically applied not only to prevent mtDNA disease but also for some infertility cases. In this review, we will interrogate the different NT techniques, including a discussion on the available safety and efficacy data of these technologies for mtDNA disease prevention. In addition, we appraise the evidence for the translational use of NT technologies in infertility. OBJECTIVE AND RATIONALE: We propose to review the current scientific evidence regarding the clinical use of NT to prevent mitochondrial disease. SEARCH METHODS: The scientific literature was investigated by searching PubMed database until Jan 2017. Relevant documents from Human Fertilisation and Embryology Authority as well as reports from both the scientific and popular media were also implemented. The above searches were based on the following key words: 'mitochondria', 'mitochondrial DNA'; 'mitochondrial DNA disease', 'fertility'; 'preimplantation genetic diagnosis', 'nuclear transfer', 'mitochondrial replacement' and 'mitochondrial donation'. OUTCOMES: While NT techniques have been shown to effectively reduce the transmission of heteroplasmic mtDNA variants in animal models, and increasing evidence supports their use to prevent the transmission of human mtDNA disease, the need for robust, long-term evaluation is still warranted. Moreover, prenatal screening would still be strongly advocated in combination with the use of these IVF-based technologies. Scientific evidence to support the use of NT and other novel reproductive techniques for infertility is currently lacking. WIDER IMPLICATIONS: It is mandatory that any new ART treatments are first adequately assessed in both animal and human models before the cautious implementation of these new therapeutic approaches is clinically undertaken. There is growing evidence to suggest that the translation of these innovative technologies into clinical practice should be cautiously adopted only in highly selected patients. Indeed, given the limited safety and efficacy data, close monitoring of any offspring remains paramount.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Craven L, Tang MX, Gorman GS, et al. Novel reproductive technologies to prevent mitochondrial disease. Hum Reprod Update. 2017. PMID: 28651360. doi:10.1093/humupd/dmx018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。